NMDA receptor activation in rat hippocampus induces cyclic GMP formation through the L-arginine-nitric oxide pathway
- PMID: 1648186
- DOI: 10.1016/0304-3940(91)90147-l
NMDA receptor activation in rat hippocampus induces cyclic GMP formation through the L-arginine-nitric oxide pathway
Abstract
When slices of young rat hippocampus were exposed briefly (2 min) to N-methyl-D-aspartate (NMDA), a rise in the levels of cyclic GMP took place. This response was dependent on NMDA concentration (EC50 approximately 30 microM) and the maximal elevations exceeded the unstimulated levels by 25-fold. The response to 100 microM NMDA was inhibited by two competitive antagonists of the conversion of arginine to nitric oxide, L-NG-methylarginine and L-NG-nitroarginine (IC50 approximately 6 microM and 100 nM respectively). The inhibitions produced by both antagonists were reduced or abolished when the incubation medium was supplemented with L-arginine (100-300 microM). Slices of adult hippocampus produced smaller increases (5-fold) in cyclic GMP levels in response to 100 microM NMDA than those found in the immature tissue, but the response could similarly be inhibited by NG-methylarginine. The results indicate that NMDA receptor activation in the hippocampus induces the generation of nitric oxide from arginine and that this novel intercellular messenger mediates the increases in cyclic GMP levels.
Similar articles
-
Activation of serotonergic 5-HT1A receptor reduces Ca(2+)- and glutamatergic receptor-evoked arachidonic acid and No/cGMP release in adult hippocampus.Neurochem Int. 1996 Apr;28(4):439-44. doi: 10.1016/0197-0186(95)00103-4. Neurochem Int. 1996. PMID: 8740452
-
Nicotine administration stimulates the in vivo N-methyl-D-aspartate receptor/nitric oxide/cyclic GMP pathway in rat hippocampus through glutamate release.Br J Pharmacol. 1998 Nov;125(5):1042-8. doi: 10.1038/sj.bjp.0702130. Br J Pharmacol. 1998. PMID: 9846643 Free PMC article.
-
Nanomolar N(G)-nitroarginine inhibits NMDA-induced cyclic GMP formation in rat cerebellum.Eur J Pharmacol. 1990 Aug 10;184(2-3):311-3. doi: 10.1016/0014-2999(90)90623-e. Eur J Pharmacol. 1990. PMID: 1964129
-
Nitric oxide-cyclic GMP pathway in brain slices.Methods Enzymol. 1996;269:129-33. doi: 10.1016/s0076-6879(96)69015-6. Methods Enzymol. 1996. PMID: 8791643 Review. No abstract available.
-
The lung in the balance: arginine, methylated arginines, and nitric oxide.Am J Physiol Lung Cell Mol Physiol. 2007 Jan;292(1):L15-7. doi: 10.1152/ajplung.00322.2006. Epub 2006 Sep 15. Am J Physiol Lung Cell Mol Physiol. 2007. PMID: 16980373 Review. No abstract available.
Cited by
-
Nitric Oxide Is Required for L-Type Ca(2+) Channel-Dependent Long-Term Potentiation in the Hippocampus.Front Synaptic Neurosci. 2016 Jun 29;8:17. doi: 10.3389/fnsyn.2016.00017. eCollection 2016. Front Synaptic Neurosci. 2016. PMID: 27445786 Free PMC article.
-
Tests of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger.Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11285-9. doi: 10.1073/pnas.88.24.11285. Proc Natl Acad Sci U S A. 1991. PMID: 1684863 Free PMC article.
-
Xenopus exhibits seasonal variation in retinotectal latency but not tecto-isthmo-tectal latency.J Comp Physiol A. 1992 Sep;171(2):207-12. doi: 10.1007/BF00188928. J Comp Physiol A. 1992. PMID: 1432856
-
A role for nitric oxide in the development of the ferret retinogeniculate projection.J Neurosci. 1996 Dec 15;16(24):7995-8004. doi: 10.1523/JNEUROSCI.16-24-07995.1996. J Neurosci. 1996. PMID: 8987826 Free PMC article.
-
Age-related changes in signal transduction. Implications for neuronal transmission and potential for drug intervention.Drugs Aging. 1994 Nov;5(5):366-90. doi: 10.2165/00002512-199405050-00006. Drugs Aging. 1994. PMID: 7833590 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources